Epigenic Therapeutics, a Shanghai, China-based biotechnology company dedicated to developing gene modulation therapy to treat prevalent diseases, raised $32M in Series A funding.
The round was co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital.
The company intends to use the funds to support the preclinical development and early clinical validation of two leading programs, discovery of future pipelines, expansion of the leadership team, and continued investments in the company’s core technology platforms.
Led by CEO Bob Zhang, Epigenic Therapeutics is a biotechnology company dedicated to developing gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.
Epigenic Therapeutics’ proprietary technology platform EPIREG™ employs its own artificial intelligence (AI) algorithms to explore and obtain an optimized CRISPR-Cas component to regulate target gene(s) or govern the expression of one or multiple gene(s) at once without changing the sequence of the DNA. Combining a proprietary lipid nanoparticle (LNP) medicine delivery system, the platform has been proven to deliver medicine to target cells and tissues ex vivo and in vivo in metabolic, cardiovascular, viral hepatitis, ocular and rare disease models.
FinSMEs
30/08/2023